GSK plc announced positive phase 3 data on May 28, 2026, for bepirovirsen, showing a 19% functional cure rate for chronic hepatitis B, significantly higher than the standard treatment's 0%. The treatment also demonstrated a 26% cure rate in patients with low viral activity, with 49% achieving desired antigen levels after one year post-treatment.